• Georgene Hergenroeder, John B Redell, Anthony N Moore, William P Dubinsky, Robert T Funk, John Crommett, Guy L Clifton, Robert Levine, Alex Valadka, and Pramod K Dash.
• Vivian L. Smith Center for Neurologic Research, University of Texas Medical School, Houston, TX, USA.
• J. Neurotrauma. 2008 Feb 1;25(2):79-93.

AbstractBrain injury biomarkers may have clinical utility in stratifying injury severity level, predicting adverse secondary events or outcomes, and monitoring the effectiveness of therapeutic interventions. As a biomarker source, serum offers several advantages over cerebrospinal fluid (CSF), including ease of accessibility and reduced risk to the patient. We screened pooled serum samples obtained from 11 severely injured traumatic brain injury (TBI) patients (Glasgow Coma Scale [GCS] 25 mm Hg). Our results support the use of serum as a source for discovery of TBI biomarkers, and indicate that serum biomarkers may have utility for predicting secondary pathologies (e.g., elevated ICP) associated with TBI.

29 keywords...

hide…